Alumis INC Form 4 insider transactions

John R. Schroer, Chief Financial Officer of Alumis Inc., sold 3,282 shares of common stock on August 3, 2026 for $26.37 per share.

Sanam Pangali, Chief Legal Officer of Alumis Inc., sold 1,364 shares of common stock on August 3, 2026 for $26.37 per share.

Roy C. Hardiman, Chief Business & Strategy Ofcr of Alumis Inc., sold 2,692 shares of common stock on August 3, 2026 for $26.37 per share.

David M Goldstein, Chief Scientific Officer of Alumis Inc., sold 2,596 shares of common stock on August 3, 2026 for $26.37 per share.

Jorn Drappa, Chief Medical Officer of Alumis Inc., sold 2,447 shares of common stock on August 3, 2026 for $26.37 per share.

Mark Christopher Bradley, Chief Development Officer of Alumis Inc., sold 2,572 shares of common stock on August 3, 2026 for $26.37 per share.

Sanam Pangali, Chief Legal Officer of Alumis Inc., reported a sale of 5,000 shares of common stock.

Alumis Inc. Director Lynn A. Tetrault acquired 3,553 shares of common stock and was granted options for 15,528 shares.

Yao Zhengbin, a Director at Alumis Inc., reported the acquisition of 3,553 shares of common stock and the grant of stock options for 15,528 shares.

Alumis Inc. director Sapna Srivastava reported transactions involving common stock and stock options, including the settlement of restricted stock units and the acquisition of stock options.

Alumis Inc. Director Patrick Machado has reported transactions involving common stock and stock options, including the acquisition of 3,553 shares via RSU settlement and the acquisition of 15,528 stock options.

Alumis Inc. Director Akkaraju Srinivas reports transactions involving restricted stock units and stock options.

Alumis Inc. Chief Medical Officer Jorn Drappa exercised stock options to acquire 26,852 shares of common stock.

Foresite Labs, LLC and its affiliates have reported significant transactions involving Alumis Inc. (ALMS) common stock, including distributions and beneficial ownership changes.

Foresite Capital Management VI LLC and related entities have reported significant changes in beneficial ownership of Alumis Inc. common stock.

Alumis Inc. director James B. Tananbaum reports significant changes in beneficial ownership of common stock, primarily through distributions from affiliated entities.

ALUMIS Inc. Chief Legal Officer Sanam Pangali was granted 186,200 stock options with an exercise price of $26.31, vesting over four years.

ALUMIS INC. President, CEO, and Chairman Martin Babler was granted 745,875 stock options with an exercise price of $26.31, vesting over four years.

ALUMIS Inc. granted 190,875 stock options to Chief Business & Strategy Officer Roy C. Hardiman with an exercise price of $26.31.

ALUMIS Inc.'s Chief Development Officer, Mark Christopher Bradley, was granted 190,225 stock options with an exercise price of $26.31.

ALUMIS Inc.'s Chief Medical Officer, Jorn Drappa, was granted 221,450 stock options with an exercise price of $26.31, vesting over four years.

ALUMIS Inc. Chief Financial Officer John R. Schroer was granted 202,225 stock options with an exercise price of $26.31, vesting over four years.

Alumis Inc.'s Chief Scientific Officer, David M. Goldstein, was granted 216,675 stock options with an exercise price of $26.31, vesting over four years.

Alumis Inc. Director Srinivas Akkaraju, through Samsara Opportunity Fund, L.P., acquired 588,235 shares of common stock for $17 per share, totaling approximately $10 million.

Foresite Labs, a 10% owner and director, increased its indirect beneficial ownership in ALUMIS INC. by acquiring 411,764 shares of common stock at $17 per share.

Foresite Capital Management VI LLC and affiliated entities reported the purchase of 411,764 shares of ALUMIS INC. common stock at $17 per share, increasing their collective indirect beneficial ownership to over 16 million shares.

James B. Tananbaum, a Director and 10% owner of ALUMIS INC., acquired 411,764 shares of common stock for $17 per share, totaling approximately $7.0 million, on January 8, 2026.

Alumis Inc. Director Srinivas Akkaraju, through affiliated funds, acquired 186,377 shares of common stock for approximately $1.83 million, signaling strong insider confidence.

Alumis Inc. Director Srinivas Akkaraju reported significant indirect purchases of common stock through Samsara Opportunity Fund, L.P. over three days in December 2025.

ALUMIS Director Srinivas Akkaraju increased his indirect beneficial ownership in the company's common stock through recent purchases by affiliated funds.